The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
New research suggests that the weight-loss medication Mounjaro may not be a worthwhile investment at its present cost. The study highlights concerns about the drug's value in relation to its price. Cost-effectiveness is questioned.
More and more fit individuals are turning to microdoses of GLP-1s, drawn by potential health benefits beyond weight loss. While some see it as a proactive approach to longevity, experts caution about the lack of research and potential risks.
Eli Lilly has announced price cuts for its weight loss medication Zepbound, aiming to improve accessibility for patients. The company is also seeking to increase the use of its digital healthcare platform, LillyDirect, through these changes.
The World Health Organization (WHO) has issued new guidelines advocating for the use of GLP-1 drugs in the treatment of obesity. These guidelines suggest that GLP-1 therapies can be used long-term by adults, excluding pregnant women, when combined with intensive behavioral therapy.
A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
